Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 11% Improvement Relative Risk HCQ for COVID-19  Rao et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 1,294 patients in India No significant difference in cases c19hcq.org Rao et al., Expert Review of Anti-infe.., Dec 2021 Favors HCQ Favors control

Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study

Rao et al., Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2022.2015326
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Prospective PrEP study with low risk healthcare workers in India showing RR=0.89 [0.53-1.52]. There were no significant adverse effects. Only mean age and gender distribution are provided for baseline characteristics, no severity information is provided, and no adjustments were made. Authors analyze HCQ use for <8 vs. ≥8 weeks, noting a lack of statistical significance, but not providing the results.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with minimal group details.
risk of case, 11.0% lower, RR 0.89, p = 0.68, treatment 16 of 273 (5.9%), control 67 of 1,021 (6.6%), NNT 143.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rao et al., 4 Dec 2021, prospective, India, peer-reviewed, 8 authors.
This PaperHCQAll
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study
Akshay Rao, Sundar Kumar Veluswamy, Banashankari Gunjiganur Shankarappa, Rithika Manjunatha Reddy, Nethravathi Umesh, Lissy John, Lysamma Mathew, Naresh Shetty
Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2022.2015326
Background: Hydroxychloroquine had attracted significant attention in the initial phases of the COVID-19 pandemic but current recommendations do not support its use. However, the evidence against its use as pre-exposure prophylaxis have been of low to moderate quality and have been limited by high risk of bias. Methods: Following institutional ethics committee approval, healthcare workers (n = 1294) completing their first week-long COVID in-patient duty, subsequent institutional quarantine and RT-PCR testing for COVID-19 infection were included for this prospective cohort study. Demographic data, hydroxychloroquine usage and related adverse effects were captured through a 'Caring for the Caregivers' surveillance system. A chi-Square test of independence was used to determine the effect of hydroxychloroquine prophylaxis. Results: Among the 1294 participants (age: 31 ± 7 years, 61% women), 273 (21.1%) healthcare workers used hydroxychloroquine prophylaxis as per Indian Council of Medical Research recommendations and 83/1294 (6.4%) tested positive after their duty. There was no significant difference in COVID-19 incidence between those on hydroxychloroquine prophylaxis and those not on it (5.9% vs 6.6%, χ 2 = 0.177, p = 0.675; RR = 0.89, 95% CI -0.53 to 1.52). There were no significant adverse effects to hydroxychloroquine usage. Conclusion: This study demonstrated no benefit of hydroxychloroquine prophylaxis and provides quality evidence against its use in COVID-19 prevention.
Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Reviewer disclosures Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Author contributions Concept and design: The study was conceived by N Shetty, A Rao and S Kumar Veluswamy. B Gunjiganur Shankarappa, L John and L Mathew contributed towards the design of the study. Data collection: A Rao, S Kumar Veluswamy. L John, L Mathew, N Umesh and R Manjunatha Reddy contributed towards data collection. Analysis: A Rao and S Kumar Veluswamy analysed the data. Writing: A Rao and S Kumar Veluswamy together wrote the first draft and all authors critically reviewed the manuscript and contributed towards the writing. Approval: All authors read and approved the final version of the manuscript for submission ORCID Akshay Rao http://orcid.org/0000-0002-4111-5424 Sundar Kumar Veluswamy http://orcid.org/0000-0003-2241-6229
References
Abella, Jolkovsky, Biney, Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern Med
Andrade, Rangel, Santos, Repurposing approved drugs for guiding COVID-19 prophylaxis: a systematic review, Front Pharmacol
Barnabas, Brown, Bershteyn, Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial, Ann Intern Med
Bergwerk, Gonen, Lustig, Covid-19 breakthrough infections in vaccinated health care workers, N Engl J Med
Bhattacharya, Chowdhury, Nandi, Pre-exposure hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective cohort, Int J Res Med Sci
Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med
Bourgeault, Maier, Dieleman, The COVID-19 pandemic presents an opportunity to develop more sustainable health workforces, Hum Resour Health
Burki, Global COVID-19 vaccine inequity, Lancet Infect Dis
Cook, Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic -a narrative review, Anaesthesia
Cruciani, Pati, Masiello, Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis, Diagnostics
Cutolo, Paolino, Smith, Evidences for a protective role of vitamin D in COVID-19, RMD Open
Dinesh, Cs, Kaur, Hydroxychloroquine for SARS CoV2 prophylaxis in healthcare workers -a multicentric cohort study assessing effectiveness and safety, J Assoc Physicians India
Grau-Pujol, Camprubí, Marti-Soler, Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial, Res Square, doi:10.21203/rs.3.rs-72132/v1
Kumar, Kubota, Chernov, Potential role of zinc supplementation in prophylaxis and treatment of COVID-19, Med Hypotheses
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Martins-Filho, Ferreira, Heimfarth, Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials, Lancet Reg Health Am
Mehra, Ruschitzka, Patel, Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Mitjà, Marc, Ubals, A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19, N Engl J Med
Nguyen, Drew, Graham, Coronavirus pandemic epidemiology consortium. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study, Lancet Public Health
Niburski, Niburski, Impact of Trump's promotion of unproven COVID-19 treatments and subsequent internet trends: observational study, J Med Internet Res
Rajasingham, Bangdiwala, Nicol, Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial, Clin Infect Dis
Reardon, Flawed ivermectin preprint highlights challenges of COVID drug studies, Nature
Singh, Chauhan, Kakkar, Hydroxychloroquine for the treatment and prophylaxis of COVID-19: the journey so far and the road ahead, Eur J Pharmacol
Stricker, Fesler, Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers from india: a meta-analysis, J Infect Public Health
{ 'DOI': '10.1080/14787210.2022.2015326', 'ISSN': ['1478-7210', '1744-8336'], 'URL': 'http://dx.doi.org/10.1080/14787210.2022.2015326', 'alternative-id': ['10.1080/14787210.2022.2015326'], 'assertion': [ { 'label': 'Peer Review Statement', 'name': 'peerreview_statement', 'order': 1, 'value': 'The publishing and review policy for this title is described in its Aims & ' 'Scope.'}, { 'URL': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierz20', 'label': 'Aim & Scope', 'name': 'aims_and_scope_url', 'order': 2, 'value': 'http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierz20'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2021-10-24'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Revised', 'name': 'revised', 'order': 1, 'value': '2021-11-18'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 2, 'value': '2021-11-22'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 3, 'value': '2021-12-04'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-4111-5424', 'affiliation': [{'name': 'Department of Internal Medicine, MS Ramaiah Medical College'}], 'authenticated-orcid': False, 'family': 'Rao', 'given': 'Akshay', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0003-2241-6229', 'affiliation': [ {'name': 'Department of Physiotherapy, MS Ramaiah Medical College'}, { 'name': 'Healthy Living for Pandemic Event Protection (HL- PIVOT) ' 'network, Chicago, Illinois, USA'}], 'authenticated-orcid': False, 'family': 'Veluswamy', 'given': 'Sundar Kumar', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Department of Microbiology, MS Ramaiah Medical College'}], 'family': 'Shankarappa', 'given': 'Banashankari Gunjiganur', 'sequence': 'additional'}, { 'affiliation': [{'name': 'MS Ramaiah Medical College'}], 'family': 'Reddy', 'given': 'Rithika Manjunatha', 'sequence': 'additional'}, { 'affiliation': [{'name': 'MS Ramaiah Medical College Hospital'}], 'family': 'Umesh', 'given': 'Nethravathi', 'sequence': 'additional'}, { 'affiliation': [{'name': 'MS Ramaiah Medical College Hospital'}], 'family': 'John', 'given': 'Lissy', 'sequence': 'additional'}, { 'affiliation': [{'name': 'MS Ramaiah Memorial Hospital'}], 'family': 'Mathew', 'given': 'Lysamma', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Caring for the Caregivers Surveillance System, MS Ramaiah ' 'Medical College Hospitals'}], 'family': 'Shetty', 'given': 'Naresh', 'sequence': 'additional'}], 'container-title': ['Expert Review of Anti-infective Therapy'], 'content-domain': {'crossmark-restriction': True, 'domain': ['www.tandfonline.com']}, 'created': {'date-parts': [[2021, 12, 4]], 'date-time': '2021-12-04T12:55:16Z', 'timestamp': 1638622516000}, 'deposited': { 'date-parts': [[2021, 12, 4]], 'date-time': '2021-12-04T12:55:25Z', 'timestamp': 1638622525000}, 'indexed': {'date-parts': [[2021, 12, 5]], 'date-time': '2021-12-05T05:47:41Z', 'timestamp': 1638683261871}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '1478-7210'}, {'type': 'electronic', 'value': '1744-8336'}], 'issued': {'date-parts': [[2021, 12, 4]]}, 'language': 'en', 'link': [ { 'URL': 'https://www.tandfonline.com/doi/pdf/10.1080/14787210.2022.2015326', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '301', 'original-title': [], 'prefix': '10.1080', 'published': {'date-parts': [[2021, 12, 4]]}, 'published-online': {'date-parts': [[2021, 12, 4]]}, 'publisher': 'Informa UK Limited', 'reference': [ {'DOI': '10.1186/s12960-020-00529-0', 'doi-asserted-by': 'publisher', 'key': 'cit0001'}, { 'key': 'cit0002', 'unstructured': '2. Nguyen LH, Drew DA, Graham MS, et al., Coronavirus Pandemic ' 'Epidemiology Consortium. Risk of COVID-19 among front-line health-care ' 'workers and the general community: a prospective cohort study. Lancet ' 'Public Health. 2020;5:e475-83.'}, {'DOI': '10.1111/anae.15071', 'doi-asserted-by': 'publisher', 'key': 'cit0003'}, {'DOI': '10.1016/j.mehy.2020.109848', 'doi-asserted-by': 'publisher', 'key': 'cit0004'}, {'DOI': '10.1136/rmdopen-2020-001454', 'doi-asserted-by': 'publisher', 'key': 'cit0005'}, { 'DOI': '10.3389/fphar.2020.590598', 'doi-asserted-by': 'crossref', 'key': 'cit0006', 'unstructured': '6. Andrade BS, Rangel FS, Santos NO, et al. Repurposing Approved Drugs ' 'for Guiding COVID-19 Prophylaxis: A Systematic Review. Front. Pharmacol. ' '2020;11:590598.'}, {'DOI': '10.1038/s41421-020-0156-0', 'doi-asserted-by': 'publisher', 'key': 'cit0007'}, {'DOI': '10.2196/20044', 'doi-asserted-by': 'publisher', 'key': 'cit0008'}, {'DOI': '10.1016/S0140-6736(20)31324-6', 'doi-asserted-by': 'publisher', 'key': 'cit0009'}, {'DOI': '10.1016/j.ejphar.2020.173717', 'doi-asserted-by': 'publisher', 'key': 'cit0010'}, { 'key': '#cr-split#-cit0011.1', 'unstructured': '11. Indian Council of Medical Research. Revised advisory on the use of ' 'Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection. ' '[Internet] 2020. [updated: 2020 May 22'}, { 'key': '#cr-split#-cit0011.2', 'unstructured': 'cited: 2021 March 18]. Available from: ' 'https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf'}, { 'DOI': '10.18203/2320-6012.ijrms20205444', 'doi-asserted-by': 'publisher', 'key': 'cit0012'}, {'DOI': '10.7326/M20-6519', 'doi-asserted-by': 'publisher', 'key': 'cit0013'}, {'DOI': '10.21203/rs.3.rs-72132/v1', 'doi-asserted-by': 'publisher', 'key': 'cit0014'}, {'DOI': '10.1001/jamainternmed.2020.6319', 'doi-asserted-by': 'publisher', 'key': 'cit0015'}, {'DOI': '10.1093/cid/ciaa1571', 'doi-asserted-by': 'publisher', 'key': 'cit0016'}, {'DOI': '10.1056/NEJMc2023617', 'doi-asserted-by': 'publisher', 'key': 'cit0017'}, { 'DOI': '10.1056/NEJMoa2021801', 'doi-asserted-by': 'crossref', 'key': 'cit0018', 'unstructured': '18. Mitjà O, Marc CM, Ubals M et al. A cluster-randomized trial of ' 'hydroxychloroquine for prevention of Covid-19. N. Engl. J. Med. ' '2021;384:417–27.'}, { 'key': 'cit0019', 'unstructured': '19. World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. ' '[Internet] 2021. [cited: 2021 October 16]. Available from: ' 'https://covid19.who.int/'}, {'DOI': '10.1016/S1473-3099(21)00344-3', 'doi-asserted-by': 'publisher', 'key': 'cit0020'}, {'DOI': '10.1016/j.jiph.2021.08.001', 'doi-asserted-by': 'publisher', 'key': 'cit0021'}, { 'key': '#cr-split#-cit0022.1', 'unstructured': '22. World Health Organisation. Coronavirus disease (COVID-19): ' 'Solidarity Trial and hydroxychloroquine. [updated: 2020 June 19'}, { 'key': '#cr-split#-cit0022.2', 'unstructured': 'cited: 2021 October 16]. Available from: ' 'https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-hydroxychloroquine.'}, {'DOI': '10.1016/j.lana.2021.100062', 'doi-asserted-by': 'publisher', 'key': 'cit0023'}, { 'key': 'cit0024', 'unstructured': '24. Dinesh B, J CS, Kaur CP et al. Hydroxychloroquine for SARS CoV2 ' 'Prophylaxis in Healthcare Workers - A Multicentric Cohort Study ' 'Assessing Effectiveness and Safety. J Assoc Physicians India. ' '2021;69(6):17-23'}, { 'key': '#cr-split#-cit0025.1', 'unstructured': '25. World Health Organization. Drugs to prevent COVID-19: A WHO living ' 'guideline. [updated: 2021 March 19'}, { 'key': '#cr-split#-cit0025.2', 'unstructured': 'cited: 2021 October 16]. Available from: ' 'https://www.who.int/publications/i/item/WHO-2019-nCoV-prophylaxes-2021-1'}, {'DOI': '10.3390/diagnostics11091645', 'doi-asserted-by': 'publisher', 'key': 'cit0026'}, {'DOI': '10.1038/d41586-021-02081-w', 'doi-asserted-by': 'publisher', 'key': 'cit0027'}, {'DOI': '10.1056/NEJMoa2109072', 'doi-asserted-by': 'publisher', 'key': 'cit0028'}], 'reference-count': 31, 'references-count': 31, 'relation': {}, 'score': 1, 'short-container-title': ['Expert Review of Anti-infective Therapy'], 'short-title': [], 'source': 'Crossref', 'subject': ['Virology', 'Infectious Diseases', 'Microbiology (medical)', 'Microbiology'], 'subtitle': [], 'title': [ 'Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare ' 'workers: a prospective cohort study'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1080/tandf_crossmark_01'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit